Vitamin D Compounds in Chronic Kidney Disease
Authors: Daniel W. Coyne
Journal: Annals of Internal Medicine (2008)

Letters17 June 2008Vitamin D Compounds in Chronic Kidney DiseaseDaniel W. Coyne, MDDaniel W. Coyne, MDFrom Washington University School of Medicine, St. Louis, MO 63110.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-148-12-200806170-00013 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The meta-analysis by Palmer and colleagues (1) concludes that vitamin D compounds “do not consistently reduce PTH levels.” Parathyroid hormone suppression by “established vitamin D” is based on only 6 studies encompassing 187 patients. Of the 5 studies I could locate, none seemed to titrate vitamin D to achieve PTH level suppression or to have PTH level suppression as a primary goal. Active vitamin D treatment did cause significant improvements in the 3 studies examining bone histology and the 1 study examining bone mineral density. Meta-analyses must carefully assess the goals of trials from differing eras. Four ...References1. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med. 2007;147:840-53. [PMID: 18087055] LinkGoogle Scholar2. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63:1483-90. [PMID: 12631365] CrossrefMedlineGoogle Scholar3. Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006;47:263-76. [PMID: 16431255] CrossrefMedlineGoogle Scholar4. Abboud H, Coyne D, Smolenski O, Anger M, Lunde N, Qiu P, et al. A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4. Am J Nephrol. 2006;26:105-14. [PMID: 16543714] CrossrefMedlineGoogle Scholar5. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72:1130-7. [PMID: 17728707] CrossrefMedlineGoogle Scholar6. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72:1004-13. [PMID: 17687259] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Washington University School of Medicine, St. Louis, MO 63110.Disclosures:Consultancies: Abbott Laboratories, INEOS. Honoraria: Abbott Laboratories. Grants received: Abbott Laboratories, Amgen. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoMeta-analysis: Vitamin D Compounds in Chronic Kidney Disease Suetonia C. Palmer , David O. McGregor , Petra Macaskill , Jonathan C. Craig , Grahame J. Elder , and Giovanni F.M. Strippoli Vitamin D Compounds in Chronic Kidney Disease Suetonia C. Palmer , Jonathan C. Craig , and Giovanni F.M. Strippoli Vitamin D Compounds in Chronic Kidney Disease Kenneth Scissors Metrics Cited byObservational Studies Versus Randomized Controlled Trials: Avenues to Causal Inference in NephrologyParicalcitol Versus Ergocalciferol for Secondary Hyperparathyroidism in CKD Stages 3 and 4: A Randomized Controlled Trial 17 June 2008Volume 148, Issue 12Page: 969-970KeywordsCalcitriolCalciumChronic kidney diseaseHypercalcemiaMedical dialysisPhosphorusRenal failureVitamin DVitamin D deficiency ePublished: 17 June 2008 Issue Published: 17 June 2008 Copyright & PermissionsCopyright © 2008 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...